Immunome (IMNM) Total Liabilities (2019 - 2026)
Immunome's (IMNM) quarterly Total Liabilities came in at $31.1 million in Q1 2026, down 12.54% YoY from $35.6 million in Q1 2025, and down 36.32% on a QoQ basis from $48.8 million in Q4 2025.
Immunome (IMNM) Total Liabilities (2019 - 2026) Analysis & Trends
Immunome (IMNM) has 8 years of Total Liabilities data on file, last reported at $31.1 million in Q1 2026.
- Quarterly Total Liabilities fell 12.54% year-over-year to $31.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $31.1 million (down 12.54% YoY) and the FY2025 annual result came in at $48.8 million, down 17.32% from the prior year.
- Total Liabilities declined to $31.1 million in Q1 2026, from $48.8 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $87.1 million in Q3 2023 to a low of $7.4 million in Q4 2022.
- A 5-year average of $33.6 million and a median of $34.2 million in 2024 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2023 — Total Liabilities jumped 1067.05% — and 2024, when it tumbled 51.78%.
- Tracing IMNM's Total Liabilities over 5 years: stood at $7.4 million in 2022, then soared by 287.64% to $28.7 million in 2023, then jumped by 106.14% to $59.1 million in 2024, then slipped by 17.32% to $48.8 million in 2025, then tumbled by 36.32% to $31.1 million in 2026.
- The last three Total Liabilities figures came in at $31.1 million (Q1 2026), $48.8 million (Q4 2025), and $35.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Immunome | 3.09 Bn | 2.57 Bn | - | 40.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 40.30 Mn |
| Mar 31, 2026 | 31.11 Mn |
| Dec 31, 2025 | 48.85 Mn |
| Sep 30, 2025 | 35.46 Mn |
| Jun 30, 2025 | 27.02 Mn |
| Mar 31, 2025 | 35.57 Mn |
| Dec 31, 2024 | 59.08 Mn |
| Sep 30, 2024 | 41.99 Mn |
| Jun 30, 2024 | 42.38 Mn |
| Mar 31, 2024 | 34.18 Mn |
| Dec 31, 2023 | 28.66 Mn |
| Sep 30, 2023 | 87.09 Mn |
| Jun 30, 2023 | 32.10 Mn |
| Mar 31, 2023 | 34.25 Mn |
| Dec 31, 2022 | 7.39 Mn |
| Sep 30, 2022 | 7.46 Mn |
| Jun 30, 2022 | 8.74 Mn |
| Mar 31, 2022 | 9.85 Mn |
| Dec 31, 2021 | 9.74 Mn |
| Sep 30, 2021 | 7.77 Mn |